Skip to main content

GlaxoSmithKline Pharmaceuticals Ltd

Stage 2 · Advancing · week 8Setup 4.5 WatchSolid +0.8

As of 9 Oct 2026, GlaxoSmithKline Pharmaceuticals is in Stage 2 — advancing, the uptrend phase, in week 8 (since 18 Aug 2026). It closed at ₹2,540, 18.2% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. More about the company

₹2,540.3
+0.23% today
₹43,034 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

4.5 Watch

Momentum

Steady

Edge

Solid +0.8

Setup-score rank among Stage 2 peers: #39 of 61 in Pharmaceuticals · #47 of 78 in Health Care

Is GLAXO early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
vs 52W High
-18.2%
₹2,103.2 lo₹3,106.4 hi
18.2% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 8
1w13w26w
Week 8 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
1.1%
200 DMA: ₹2,512.3 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.34x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -4.5% vs MA50 +4.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-13.2%
3M
+4.2%
6M
+7.9%
YTD
+1.6%
1Y
-5.8%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #60 of 74 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #47 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 38w
S2 21w
S2 17w
S4 19w
S4 17w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 38w → S3 8w → S2 21w → S3 9w → S4 9w → S1 6w → S2 17w → S3 10w → S4 19w → S1 4w → S4 17w → S1 3w → S2 8w current
Total tracked: 168 weeks across 13 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-08-18
3 appearances in last 60 days. First seen: 2024-05-29.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 8 · Vol 0.34x
2026-10-08S2
Wk 8 · Vol 0.53x
2026-10-07S2
Wk 7 · Vol 1.03x
2026-10-06S2
Wk 7 · Vol 0.32x
2026-10-05S2
Wk 7 · Vol 0.20x
2026-10-01S2
Wk 7 · Vol 0.60x
2026-09-30S2
Wk 7 · Vol 0.37x
2026-09-29S2
Wk 6 · Vol 0.40x
2026-09-28S2
Wk 6 · Vol 3.99x
2026-09-25S2
Wk 6 · Vol 0.13x
2026-09-24S2
Wk 6 · Vol 0.15x
2026-09-23S2
Wk 6 · Vol 1.42x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹2,809.1
200 DMA
₹2,512.3
52W High
₹3,106.4
52W Low
₹2,103.2
5D Low
₹2,534.4
Resistance levels (recent highs)
20d High
₹2,896.4
60d High
₹3,106.4
120d High
₹3,106.4
250d High
₹3,106.4
Next resistance
+14.0%
to 20d High
P/E (TTM)
38.3
Forward 29.7
Earnings Growth (YoY)
+5.7%
Revenue +2.1%
ROE
+49.1%
Profit margin +27.1%
Dividend Yield
2.50%
P/B 22.8
About this companyHealth Care· Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states; Flutivate, a skin cream for adults, children, and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is based in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.